These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

343 related items for PubMed ID: 22357577

  • 1. Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial.
    Ambrosy AP, Vaduganathan M, Huffman MD, Khan S, Kwasny MJ, Fought AJ, Maggioni AP, Swedberg K, Konstam MA, Zannad F, Gheorghiade M, EVEREST trial investigators.
    Eur J Heart Fail; 2012 Mar; 14(3):302-11. PubMed ID: 22357577
    [Abstract] [Full Text] [Related]

  • 2. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial.
    Ambrosy AP, Vaduganathan M, Mentz RJ, Greene SJ, Subačius H, Konstam MA, Maggioni AP, Swedberg K, Gheorghiade M.
    Am Heart J; 2013 Feb; 165(2):216-25. PubMed ID: 23351825
    [Abstract] [Full Text] [Related]

  • 3. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial.
    Blair JE, Pang PS, Schrier RW, Metra M, Traver B, Cook T, Campia U, Ambrosy A, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Konstam MA, Gheorghiade M, EVEREST Investigators.
    Eur Heart J; 2011 Oct; 32(20):2563-72. PubMed ID: 21785107
    [Abstract] [Full Text] [Related]

  • 4. Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial).
    Greene SJ, Vaduganathan M, Lupi L, Ambrosy AP, Mentz RJ, Konstam MA, Nodari S, Subacius HP, Fonarow GC, Bonow RO, Gheorghiade M, EVEREST Trial Investigators.
    Am J Cardiol; 2013 Feb 15; 111(4):574-81. PubMed ID: 23206923
    [Abstract] [Full Text] [Related]

  • 5. Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial).
    Khan SS, Campia U, Chioncel O, Zannad F, Rossignol P, Maggioni AP, Swedberg K, Konstam MA, Senni M, Nodari S, Vaduganathan M, Subacius H, Butler J, Gheorghiade M, EVEREST Trial Investigators.
    Am J Cardiol; 2015 Mar 15; 115(6):790-6. PubMed ID: 25728846
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. De Ritis ratio as diagnostic marker of alcoholic liver disease.
    Majhi S, Baral N, Lamsal M, Mehta KD.
    Nepal Med Coll J; 2006 Mar 15; 8(1):40-2. PubMed ID: 16827089
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial.
    Girerd N, Pang PS, Swedberg K, Fought A, Kwasny MJ, Subacius H, Konstam MA, Maggioni A, Gheorghiade M, Zannad F, EVEREST investigators.
    Eur J Heart Fail; 2013 Nov 15; 15(11):1228-35. PubMed ID: 23787720
    [Abstract] [Full Text] [Related]

  • 11. Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial).
    Shah AN, Mentz RJ, Gheorghiade M, Kwasny MJ, Fought AJ, Zannad F, Swedberg K, Maggioni AP, Konstam MA.
    Am J Cardiol; 2012 Dec 15; 110(12):1803-8. PubMed ID: 22999071
    [Abstract] [Full Text] [Related]

  • 12. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program.
    Blair JE, Zannad F, Konstam MA, Cook T, Traver B, Burnett JC, Grinfeld L, Krasa H, Maggioni AP, Orlandi C, Swedberg K, Udelson JE, Zimmer C, Gheorghiade M, EVEREST Investigators.
    J Am Coll Cardiol; 2008 Nov 11; 52(20):1640-8. PubMed ID: 18992654
    [Abstract] [Full Text] [Related]

  • 13. Liver function, in-hospital, and post-discharge clinical outcome in patients with acute heart failure-results from the relaxin for the treatment of patients with acute heart failure study.
    van Deursen VM, Edwards C, Cotter G, Davison BA, Damman K, Teerlink JR, Metra M, Felker GM, Ponikowski P, Unemori E, Severin T, Voors AA.
    J Card Fail; 2014 Jun 11; 20(6):407-13. PubMed ID: 24642379
    [Abstract] [Full Text] [Related]

  • 14. Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure.
    Nikolaou M, Parissis J, Yilmaz MB, Seronde MF, Kivikko M, Laribi S, Paugam-Burtz C, Cai D, Pohjanjousi P, Laterre PF, Deye N, Poder P, Cohen-Solal A, Mebazaa A.
    Eur Heart J; 2013 Mar 11; 34(10):742-9. PubMed ID: 23091203
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial.
    Blair JE, Khan S, Konstam MA, Swedberg K, Zannad F, Burnett JC, Grinfeld L, Maggioni AP, Udelson JE, Zimmer CA, Ouyang J, Chen CF, Gheorghiade M, EVEREST Investigators.
    Eur Heart J; 2009 Jul 11; 30(13):1666-73. PubMed ID: 19411662
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the PROTECT study.
    Biegus J, Hillege HL, Postmus D, Valente MA, Bloomfield DM, Cleland JG, Cotter G, Davison BA, Dittrich HC, Fiuzat M, Givertz MM, Massie BM, Metra M, Teerlink JR, Voors AA, O'Connor CM, Ponikowski P.
    Eur J Heart Fail; 2016 Jul 11; 18(7):830-9. PubMed ID: 27170455
    [Abstract] [Full Text] [Related]

  • 20. Association of low body temperature and poor outcomes in patients admitted with worsening heart failure: a substudy of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial.
    Payvar S, Spertus JA, Miller AB, Casscells SW, Pang PS, Zannad F, Swedberg K, Maggioni AP, Reid KJ, Gheorghiade M, Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Investigators.
    Eur J Heart Fail; 2013 Dec 11; 15(12):1382-9. PubMed ID: 23858000
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.